Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E L Nasonov

Showing results (11-20 of 476) with videos related to

Pageof 48
Sort By:
Terapevticheskii Arkhiv|October 26, 2022
[2019 Coronavirus disease (COVID-19): contribution of rheumatology]E L Nasonov
Terapevticheskii Arkhiv|October 26, 2022
[Janus kinase inhibitors in immunoinflammatory rheumatic diseases]E L Nasonov
Klinicheskaia Meditsina|January 1, 1989
[The antiphospholipid syndrome: clinical and immunological aspects]E L Nasonov
Terapevticheskii Arkhiv|February 1, 2017
[Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations]E L Nasonov
Kardiologiia|December 21, 2002
[Osteoporosis and cardiovascular diseases]E L Nasonov
Terapevticheskii Arkhiv|January 8, 2000
[Cyclooxygenase-2 inhibitors: current concepts (lecture)]E L Nasonov
Terapevticheskii Arkhiv|July 3, 2004
[Rheumatoid arthritis as a general medical problem]E L Nasonov
Terapevticheskii Arkhiv|January 1, 1990
[Infection with the human immunodeficiency virus, rheumatic pathology and autoimmunity]E L Nasonov
Klinicheskaia Meditsina|June 30, 1998
[Problems of osteoporosis: study of biochemical markers of bone metabolism]E L Nasonov
Terapevticheskii Arkhiv|June 25, 2025
[Advances in pharmacotherapy for immunoinflammatory rheumatic diseases in the 21st century]E L Nasonov
Pageof 48

Showing results (11-20 of 476) with videos related to

Sort By:
Pageof 48
Terapevticheskii Arkhiv|October 26, 2022
[2019 Coronavirus disease (COVID-19): contribution of rheumatology]E L Nasonov
Terapevticheskii Arkhiv|October 26, 2022
[Janus kinase inhibitors in immunoinflammatory rheumatic diseases]E L Nasonov
Klinicheskaia Meditsina|January 1, 1989
[The antiphospholipid syndrome: clinical and immunological aspects]E L Nasonov
Terapevticheskii Arkhiv|February 1, 2017
[Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations]E L Nasonov
Kardiologiia|December 21, 2002
[Osteoporosis and cardiovascular diseases]E L Nasonov
Terapevticheskii Arkhiv|January 8, 2000
[Cyclooxygenase-2 inhibitors: current concepts (lecture)]E L Nasonov
Terapevticheskii Arkhiv|July 3, 2004
[Rheumatoid arthritis as a general medical problem]E L Nasonov
Terapevticheskii Arkhiv|January 1, 1990
[Infection with the human immunodeficiency virus, rheumatic pathology and autoimmunity]E L Nasonov
Klinicheskaia Meditsina|June 30, 1998
[Problems of osteoporosis: study of biochemical markers of bone metabolism]E L Nasonov
Terapevticheskii Arkhiv|June 25, 2025
[Advances in pharmacotherapy for immunoinflammatory rheumatic diseases in the 21st century]E L Nasonov
Pageof 48